> Community > Stories > Making sense of immune response data for precision oncology
01.02
2022

Making sense of immune response data for precision oncology

Biopôle’s entrepreneur share: Dr Sahar Hosseinian Ehrensberger

Dr Sahar Hosseinian tells us about her journey to entrepreneurship and shares her top tips to succeed in today’s competitive market.

 

How did you get to where you are today?

I’m from Iran and moved to Switzerland over two decades ago. I studied here, became a data scientist in mathematical modelling and lectured at the EPFL for three years. Then I got to the point where I asked myself, should I work for a big pharma company as a way of using my knowledge or should I go to a start-up? I met two biologists who were hugely inspiring and had amazing data that leveraged the host response in cancer patients to save their lives. It was a no-brainer – I decided to help them analyse their data and develop an early colorectal cancer detection test. And the more I analysed the immune response data, the more I saw we can learn from data. I didn’t know at the time that the three of us would co-found Novigenix together.

How did you go from analysing data to starting your own company?

The immune system is dynamically responsive, and I found it incredible that we can take immune response data and turn it into information that helps patients. I became more and more interested in starting a business and commercialising our products, so we founded Novigenix in 2014. Personally, I believe that data-driven, precision medicine solutions will revolutionise the way we detect disease and develop drugs.

And what does Novigenix do?

At Novigenix, we analyse immuno-transcriptomic data with the application of artificial intelligence to create mRNA biomarkers in precision oncology. This means that, from a patient’s blood sample, we extract RNA to get a full image of their immune response.
Our scientific team has unique experience in getting information out of a huge amount of mRNA data. This can then be used to detect and monitor disease to improve patient outcomes. We can see, for example, if someone is at risk of developing certain types of hereditary cancers, or help biopharma with their drug development phases by providing actionable biomarkers.

I was a driven scientist, but you really have to fight for your ideas to convince others of their value.

Being an entrepreneur takes a lot of determination. What has helped or inspired you along the way?

I learnt a lot from my father, who was a senior army officer. He used to tell me that if you want something, you have to fight for it. You have to be brave and not afraid of failure. This is advice I’ve always tried to follow. I was a driven scientist, but you really have to fight for your ideas to convince others of their value. As an Iranian women, you learn to live with challenges.

What is your biggest strength?

I’m not someone who gives up. I’m the mother of two baby boys (although I probably can’t call them babies any more – they are 6 and 9 years old!) and at home we try to teach them to be resilient. When they’re frustrated in their games, we tell them that in life, we don’t lose – we’re here to learn every day.

Why did you choose Biopôle for your company?

We were one of the very first companies at Biopôle; we’ve been here for seven or eight years. We’ve seen Biopôle grow over this time and become a great hub for life sciences companies. There are lots of options for different collaborations and we’ve built many networks here. Biopôle does a phenomenal job of gathering people together through lab sharing and other initiatives. And they have solutions for anyone wanting to join – big companies, small companies, start-ups.

What are your tips for young entrepreneurs?

  1.  Keep it simple. If you meet investors for your idea, you need to be convincing. And to do this, the best way is to tell them in simple terms what your ideas are.
  2. Listen to others. There’s so much we can learn from each other. Sometimes we think our idea is the best, but anyone around us could have a brilliant idea that takes us in a new direction. Work as a team and play to each other’s strengths.
  3. Trust others. When you scale up, you need to be able to step back and delegate. There are different ways of doing things – not just your own ways.
  4. Learn every day. Be open to change and new perspectives.
  5. Be brave and accept failure. Recognise it, accept it and persevere.
Dr Sahar Hosseinian
Co-founder and Chief Technology Officer at Novigenix SA
Sahar is a visionary entrepreneur who is Co-founder and Chief Technology Officer of Novigenix SA, a Swiss molecular diagnostic company specialised in precision medicine solutions for early detection and therapy response prediction in oncology. She has more than 14 years of experience in industry of in vitro diagnostics, with management responsibilities in the fields of data science, clinical affairs and business development. Sahar was a key contributor in the company’s strategy development from early stages to commercial activity.

Sahar obtained her PhD in applied statistics in 2009 and the Certificate of Advanced Studies in Management of Biotech Medtech and Pharma Ventures in 2012, from the Swiss Institute of Technology in Lausanne (EPFL). She was also a lecturer at the EPFL for applied statistics for life sciences.

Novigenix
Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for the detection of disease, therapy optimization, and disease recurrence monitoring to improve disease management and patient outcomes. The Novigenix proprietary LITOseek platform is optimized for mapping the response of the immune system to onset and progression of disease by integrating patient multi-omics data, advanced Machine Learning, and artificial intelligence approaches, to provide actionable insights and precision solutions for optimization of patient’s therapeutic journey.
View company

COMMUNITY STORIES, THAT MAKE US PROUD

Interview with Laurent Christe, Senior Engagement Manager at Swiss Post
Discover
Interview with Prof. Michel Prudent, Head of Research and Development Products at Transfusion Interrégionale CRS
Discover
How digital health is transforming patient journeys
Discover